Skip to main content


Current treatment guidelines recommend sequential hormone therapy for patients with hormone receptor-positive (HR+) metastatic breast cancer who are not in visceral crisis and whose disease is not refractory to endocrine treatment. Second-line fulvestrant monotherapy is a treatment option for patients in whom disease progresses after first-line palbociclib. Researchers used real-world data to evaluate the time to treatment discontinuation (TTD) of second-line fulvestrant in patients with HR+ human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer who did (n = 88) and did not (n = 100) receive first-line palbociclib and found it was shorter in patients who received palbociclib. They presented the findings at the San Antonio Breast Cancer Symposium on December 7, 2018.

Our Spirit. Our Practice.

ONS Members Share Education, Resources in Peru
ONS Members Share Education, Resources in Peru

“If you know other countries and their people, there will be no wars or hatred.” That was the motto I understood when I was younger and I remember participating in international oncology and nursing conferences, exchanging knowledge, resources, and education with other countries. Cancer connects us all, and that maxim has stuck with me and marked my interest in travelling and meeting new people.

View All Stories